Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kakavanos, Revecca"'
Autor:
Kakavanos, Revecca
"February, 2006"
Addendum attached to back page.
Bibliography: leaves 173-206.
xii, 206 leaves : ill. (chiefly col.), plates, photographs (chiefly col.) ; 30 cm.
Title page, contents and abstract only. The complete thesis in print
Addendum attached to back page.
Bibliography: leaves 173-206.
xii, 206 leaves : ill. (chiefly col.), plates, photographs (chiefly col.) ; 30 cm.
Title page, contents and abstract only. The complete thesis in print
Externí odkaz:
http://hdl.handle.net/2440/22364
Publikováno v:
In The Lancet 10 May 2003 361(9369):1608-1613
Publikováno v:
In Trends in Molecular Medicine 2003 9(10):450-453
Autor:
Kakavanos, Revecca, Lehn, Pierre, Callebaut, Isabelle, Meikle, Peter J., Parkinson-Lawrence, Emma J., Hopwood, John J., Brooks, Doug A.
Publikováno v:
In FEBS Letters 2006 580(1):87-92
Publikováno v:
In FEBS Letters 2006 580(18):4365-4370
Publikováno v:
FEBS letters. 580(18)
alpha-Glucosidase (EC 3.2.1.3) is a lysosomal enzyme that hydrolyses alpha-1,4- and alpha-1,6-linkages of glycogen to produce free glucose. A deficiency in alpha-glucosidase activity results in glycogen storage disorder type II (GSD II), also called
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a14005b7ccd435163e0092efd05c7233
https://pubmed.ncbi.nlm.nih.gov/16846599
https://pubmed.ncbi.nlm.nih.gov/16846599
Autor:
Isabelle Callebaut, John J. Hopwood, Peter J. Meikle, Revecca Kakavanos, Doug A. Brooks, Pierre Lehn, Emma J. Parkinson-Lawrence
Publikováno v:
FEBS Letters
FEBS Letters, Wiley, 2006, 580, pp.87-92. ⟨10.1016/j.febslet.2005.11.053⟩
FEBS Letters, Wiley, 2006, 281, pp.6850-6859. ⟨10.1016/j.febslet.2005.11.053⟩
FEBS Letters, 2006, 580, pp.87-92. ⟨10.1016/j.febslet.2005.11.053⟩
FEBS Letters, Wiley, 2006, 580, pp.87-92. ⟨10.1016/j.febslet.2005.11.053⟩
FEBS Letters, Wiley, 2006, 281, pp.6850-6859. ⟨10.1016/j.febslet.2005.11.053⟩
FEBS Letters, 2006, 580, pp.87-92. ⟨10.1016/j.febslet.2005.11.053⟩
Enzyme replacement therapy (ERT) has proven to be an effective therapy for some lysosomal storage disorder (LSD) patients. A potential complication during ERT is the generation of an immune response against the replacement protein. We have investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::819246971242dfcf190fb2d1bb262a0e
https://hdl.handle.net/1959.8/42396
https://hdl.handle.net/1959.8/42396
Publikováno v:
Lancet (London, England). 361(9369)
Summary Background Enzyme-replacement therapy has been assessed as a treatment for patients who have mucopolysaccharidosis I (α-L-iduronidase deficiency). We aimed to investigate the humoral immune response to recombinant human α-L-iduronidase amon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38acd7f2342f00b8cd76b6893398bee6
https://pubmed.ncbi.nlm.nih.gov/12747881
https://pubmed.ncbi.nlm.nih.gov/12747881
Lysosomal storage disorders are collectively important because they cause significant morbidity and mortality. Patients can present with severe symptoms that include somatic tissue and bone pathology, developmental delay and neurological impairment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aa20a49e3e8ca8e79459f7ed8434d97
https://hdl.handle.net/1959.8/42406
https://hdl.handle.net/1959.8/42406